Price (delayed)
$10.69
Market cap
$679.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.81
Enterprise value
$722.77M
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only ...
Highlights
EOLS's gross profit is up by 33% year-on-year and by 7% since the previous quarter
Evolus's revenue has increased by 32% YoY and by 7% QoQ
Evolus's equity has surged by 127% YoY but it has decreased by 6% QoQ
The debt rose by 2.7% year-on-year
Key stats
What are the main financial stats of EOLS
MarketValuationsEarnings
Shares outstanding
63.59M
Market cap
$679.74M
Enterprise value
$722.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
122.58
Price to sales (P/S)
2.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
Revenue
$266.27M
Gross profit
$182.3M
Operating income
-$34.41M
Net income
-$50.42M
EBIT
-$31.02M
EBITDA
-$25M
Free cash flow
-$22.82M
Per shareBalance sheetLiquidity
EPS
-$0.81
EPS diluted
-$0.81
Free cash flow per share
-$0.37
Book value per share
$0.09
Revenue per share
$4.29
TBVPS
$2.62
Total assets
$232.57M
Total liabilities
$227.05M
Debt
$129.98M
Equity
$5.52M
Working capital
$88.38M
Debt to equity
23.54
Current ratio
2.4
Quick ratio
2.14
Net debt/EBITDA
-1.72
MarginsEfficiencyDividend
EBITDA margin
-9.4%
Gross margin
68.5%
Net margin
-18.9%
Operating margin
-12.9%
Return on assets
-21.9%
Return on equity
-410.2%
Return on invested capital
-21.6%
Return on capital employed
-18.3%
Return on sales
-11.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EOLS stock price
How has the Evolus stock price performed over time
Intraday
-6.15%
1 week
-11.29%
1 month
-25.51%
1 year
-20.34%
YTD
-3.17%
QTD
-11.14%
Financial performance
How have Evolus's revenue and profit performed over time
Revenue
$266.27M
Gross profit
$182.3M
Operating income
-$34.41M
Net income
-$50.42M
Gross margin
68.5%
Net margin
-18.9%
EOLS financials
The company's operating margin rose by 47% YoY and by 21% QoQ
The net margin rose by 38% year-on-year and by 15% since the previous quarter
EOLS's gross profit is up by 33% year-on-year and by 7% since the previous quarter
Evolus's revenue has increased by 32% YoY and by 7% QoQ
Growth
What is Evolus's growth rate over time
EOLS growth chart
Valuation
What is Evolus stock price valuation
P/E
N/A
P/B
122.58
P/S
2.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
Price to earnings (P/E)
The company's EPS rose by 25% YoY and by 10% QoQ
Price to book (P/B)
Evolus's equity has surged by 127% YoY but it has decreased by 6% QoQ
EOLS's P/B is 29% above its last 4 quarters average of 94.8
Price to sales (P/S)
The P/S is 36% less than the 5-year quarterly average of 3.9 and 25% less than the last 4 quarters average of 3.3
Evolus's revenue has increased by 32% YoY and by 7% QoQ
Efficiency
How efficient is Evolus business performance
The company's return on equity has surged by 58% QoQ
The company's return on sales has surged by 50% YoY and by 21% QoQ
The ROIC has grown by 48% YoY and by 17% from the previous quarter
Evolus's ROA has increased by 39% YoY and by 13% from the previous quarter
Dividends
What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EOLS.
Financial health
How did Evolus financials performed over time
Assets vs liabilities
The total assets is 2.4% more than the total liabilities
The total assets has increased by 23% YoY
The quick ratio has grown by 11% year-on-year
Debt vs equity
Evolus's equity has surged by 127% YoY but it has decreased by 6% QoQ
Evolus's debt to equity has increased by 7% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.